BioVie Inc. announced on November 4, 2024, that its upcoming PD-202 clinical trial, a double-blind, randomized, placebo-controlled study of bezisterim in subjects with early Parkinson’s Disease, is now fully funded.
The company stated that favorable capital market conditions in the preceding week enabled the full funding of this important study. This ensures that the trial can proceed without financial constraints.
The PD-202 trial is a critical component of BioVie's neurodegenerative pipeline, evaluating its anti-inflammatory, insulin-sensitizing candidate bezisterim for a significant unmet medical need.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.